AUTHORS
Sofiane Fodil, MD, Lucie Biard, MD, PhD2, Marie Sébert, MD, PhD3, Nicolas Vallet, MD, PhD4, Kim Pacchiardi5, Thomas Cluzeau, MD, PhD6, Loiseau Aude7, Rudy Birsen, MD, PhD8, Anouk Walter-Petrich9, Mael Heiblig, MD10, Delphine Lebon, MD, PhD11, Morgane Fontaine12, Catherine Lonchamp13, Renaud Buffet, MD14, Alexandre Puissant, PhD15, Lila Nessah16, Lauriane Goldwirt, MD, PhD17, Laure Gilles18, Raphael Itzykson, MD, PhD19
AFFILIATIONS
1 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
2 Service de Biostatistique et Information Médicale, Hôpital Saint Louis, AP-HP, Paris, France
3 Senior Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
4 Hematology and Cell Therapy Department, Tours University Hospital, Tours, France
5 Inserm U1342, IRSL, Paris Saint-Louis Leukemia Institute, Saint Louis Hospital, University of Paris-Cité, Paris., Paris, France
6 CHU Nice-Hôpital de l'Archet 1 Nice France, Nice, France
7 Pharmacology Department, AP-HP, Hôpital Saint-Louis, Paris, Paris, France
8 Service d’Hématologie Clinique, Hôpital Cochin, AP-HP, Paris, Paris, France
9 Service de Biostatistique et Information Médicale, Hôpital Saint Louis, AP-HP, Paris, France
10 Centre Hospitalier Lyon Sud, Lyon, France
11 CHU AMIENS, Amiens, France
12 Inserm U1342, IRSL, Paris Saint-Louis Leukemia Institute, Saint Louis Hospital, University of Paris-Cité, Paris., Paris, France
13 Inserm U1342, IRSL, Paris Saint-Louis Leukemia Institute, Saint Louis Hospital, University of Paris-Cité, Paris., Paris, France
14 ALFA, Paris, France
15 Inserm U1342, IRSL, Paris Saint-Louis Leukemia Institute, Saint Louis Hospital, University of Paris-Cité, Paris., Paris, France
16 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
17 Pharmacology Department, AP-HP, Hôpital Saint-Louis, Paris, Paris, France
18 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
19 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
ABSTRACT
Context. Ferroptosis is a regulated cell death process gaining increasing attention for the treatment of cancers. Sulfasalazine (SSZ) can be repurposed to inhibit cystine import, triggering oxidative stress and ferroptosis. Preclinical data support its combination with anthracyclines in AML (Pardieu et al. Leukemia 2022). We report the results of the phase I part of a trial assessing the safety and preliminary efficacy of addition of SSZ to a single 3+7 induction course in fit AML patients aged 60 years (y) or older.
Methods. The SALMA trial (NCT05580861) is a prospective, multicenter phase I/II enrolling patients ≥ 60y with newly-diagnosed, FLT3 wildtype AML with intermediate or adverse cytogenetics suited for intensive chemotherapy. The phase I dose-escalation part was designed using a survival continual reassessment method (surv-CRM, Andrillon et al. J Biopharm Stat 2020) to identify the maximal tolerated dose (MTD) and recommended phase II dose (RP2D) across 6 dose levels (DL) of oral sulfasalazine (SSZ) starting from DL1 (0.5 g t.i.d, day [d] -1 to 14), combined with standard 3+7 induction chemotherapy (idarubicine [IDA] 12 mg/m²/d d1-3, cytarabine [AraC] 200 mg/m²/d d1-7). DLTs were defined as grade ≥ 3 myelosuppression without morphological evidence of leukemia at day 42, grade ≥ 3 hemorrhage or non-hematological AE (except grade 3 febrile neutropenia or TLS). Key secondary endpoints included response per ELN 2022 criteria and centralized flow and NPM1 MRD, SSZ pharmacokinetics (PK) and pharmacodynamics (PD).
Results. Between 03/2023 and 03/2026, 22 patients (pts) were screened and 20 (M/F12/8) accrued in 6 centers. Median age was 66.4 years (IQR, 63.8-70.5). AML ontogeny was de novo, secondary to MDS and associated with germline predisposition in 15, 4, 1 pts, resp. Median WBC count was 3.6 G/L (IQR, 2.6-9.2) and ELN22 risk was favorable, intermediate and adverse in 10, 3 and 7 pts, resp. Median HCT-CI was 0 (IQR, 0-1).
Following the surv-CRM design, 12 pts were assigned to DL1, 1 to DL-1 (SSZ 0.5 g t.i.d, day [d] -1 to 7) and 7 to DL2 (SSZ 1.0 g t.i.d, day [d] -1 to 14). 3 DLTs occurred at DL1 (acute respiratory distress, cardiac failure during sepsis, and myocardial infarction) and 3 DLTs occurred at DL2 (acute heart failure considered unrelated to study treatment, generalized maculopapular rash, and worsening of pre-existing pulmonary infection). Based on the target DLT rate of 33%, and prior assumptions on DLT rates across DLs, DL2 was identified as the MTD. Grade ≥3 AEs occurring in ≥2 pts included gastrointestinal, respiratory, administration site, infectious, cutaneous, and metabolic/nutritional disorders (2 pts each).
In the first 19 pts who reached the end of induction visit, 12 (63%) achieved CR and 4 (21%) CRi; the remaining 3 had no response, translating into CRc and ORR rates of 84%. Flow based MRD (LAIP/DfN) was < 0.1% in 13 pts, all of whom had achieved CRc, translating into a CR-MRDneg rate of 68.4% after a single induction course. CRc and CR-MRDneg rates were 90% and 70% in pts with intermediate or adverse ELN22 risk. Among the 10 pts with NPM1 mutations, NPM1 MRD was < 10-3 in the BM in 5 cases and < 10-4 in the PB in 4 cases. Follow-up data will be presented.
Preliminary PK analysis could be conducted in 6 pts (3 at DL1, 1 at DL-1 and 2 at DL2). At steady state (day 14) Median (IQR) SSZ trough plasma concentrations reached 21.2 [13.6 – 25.9] mg/L, exceeding the 3d quartile of SSZ IC50 generated by ex vivo drug sensitivity testing in a series of 164 AML samples (PMID 35750691). Induction of oxidative stress was inspected by flow cytometry (CellROX) in patients pre/post SSZ dosing at day 0 (pre-IDA/AraC) and day 1 (after first administration of IDA/AraC). Induction of oxidative stress in gated blasts upon SSZ was notable in 5/13 (38%, one-sample Wilcoxon test for change in CellROX as continuous variable: p=1) patients at day 0, and 8/10 (80%, one-sample Wilcoxon test p=0.03) patients at day 1.
Conclusion. Addition of sulfasalazine to conventional 3+7 induction chemotherapy in newly diagnosed AML patients is safe and triggers oxidative stress in vivo. Preliminary efficacy data is suggestive of high rates of deep early responses. Phase II accrual is ongoing to demonstrate increased rates of CR-MRDneg and explore efficacy compared to a synthetic control arm from the ALFAPPP cohort (NCT04777916).
DISCLOSURES
Sofiane Fodil, MD: No relevant conflicts of interest to declare.